November 3, 2026 17 min read

Pfizer (PFE) — Q3 FY2026 Earnings Briefing

Fiscal period: Q3 FY2026 · Report date: November 3, 2026

Executive Summary

A beat-and-raise quarter: revenue of $16.6B came in ahead of expectation and adjusted diluted EPS of $0.87 exceeded plan even while absorbing a $0.10-per-share charge for the Innovent transaction that closed in the quarter.
Full-year revenue and adjusted EPS guidance were raised while that charge was being absorbed — management’s central confidence signal, built on the launched-and-acquired growth engine and an on-track cost program.
Oncology, immunology, pneumococcal, and metabolic proof points arrived in force, supporting the claim that the post-2028 growth ambition rests on more than a single franchise.
The tension is the hand-off: momentum is front-loaded in an acquired-portfolio ramp and a Q4-heavy COVID season, while the 2027 LOE stack (U.S. Ibrance/Xtandi, international Eliquis exiting at end-2026) and a fresh pricing-policy regime cap what the guide can absorb.
Formal 2027 guidance lands in mid-December, turning the bridge from aspiration to arithmetic.

Highlights and Lowlights

Highlights

Full-year 2026 revenue guidance was raised $1.5B at the midpoint to $62–64B, and adjusted EPS was raised and narrowed to $2.95–3.05 while absorbing the Innovent charge rather than spending into it.
Launched and acquired products grew 32% YoY operationally, with Padcev, Nurtec, and Lorbrena the primary contributors to the cohort the company is spending behind to counter pending LOEs.
First-line NSCLC response rates for the PD-1/VEGF bispecific tevonatamab reached approximately 80% on the pivotal dose with doublet chemotherapy, up roughly twenty percentage points since the prior analysis.
The latest elranatamab readout in double-class-exposed multiple myeloma (MM-32) showed a statistically significant, clinically meaningful PFS benefit over three established regimens, with an estimated 18-month PFS of about 68% at interim.
Atemaciclib’s FORLIGHT-1 Phase 2 cut the risk of disease progression or death by 40% versus investigator’s choice in heavily pretreated HR+ breast cancer after CDK4/6 inhibitor discontinuation.
Pediatric PCV25 met the historically used serology criterion across its Phase 2, with modeling predicting at least 22 of 25 serotypes will clear the FDA’s tougher 1.5-fold non-inferiority bar in the pivotal trial.
The first-phase cost program is on track, with nearly all of the targeted $7.2B of net savings expected to be delivered by the end of 2026.

Lowlights

COVID products are guided to approximately $4B for FY2026, leaving the majority of Comirnaty revenue dependent on a Q4 vaccination season and Paxlovid hostage to infection rates.
The 2027 bridge absorbs U.S. LOEs on Ibrance and Xtandi plus the international Eliquis LOE at the end of 2026, with share repurchases staying on the sideline until the LOE transition completes.
An expected net-price impact of the January 1 U.S. Eliquis price decrease began landing in Q3, the only gross-to-net move flagged in an otherwise stable quarter that management attributed mostly to volume and market execution.
Pricing policy stacks into 2027, with two Pfizer products entering Medicare’s negotiated-price program, the 340B credit/rebate model starting in January, and government-agreement (MFN) impacts landing on top.
Q3 SG&A carried one-time dynamics that pushed it higher, and total spending has not come down structurally — SG&A plus R&D was about $24.5B in 2022 and again at roughly the same level in 2026, an analyst-provided baseline the CFO did not dispute.
The Prevnar family joined COVID products among the quarter’s decliners, with no offsetting vaccine strength offered against it.
The Street remains under-modeled: per Bourla, only 5 of 12–13 analysts embed the pipeline in their P&Ls, leaving the growth story dependent on sell-side re-modeling.

1. The Quarter in Numbers

Metric	Q3 FY2026	Notes
Revenue	$16.6B	Ahead of expectation; strong non-COVID performance offset lower COVID revenue
Non-COVID operational growth	+7% YoY	Driven by key brands in the U.S. and select international markets
Adjusted diluted EPS	$0.87	Beat expectation; includes the $0.10 Innovent AIP R&D charge
Reported diluted EPS	$0.56	GAAP basis
Adjusted gross margin	77%	Reflecting favorable product mix and continued cost management
Adjusted operating expenses	$6.8B	S&I +2% YoY operationally; R&D +18% YoY operationally; acquired IPR&D −52% YoY operationally
Adjusted operating margin	36%	Tempered by the Innovent AIP R&D charge, otherwise supported by cost management and non-COVID strength

The expense detail inside the $6.8B defines the quarter’s operating character. S&I rose 2% YoY operationally as a lower favorable adjustment for U.S. healthcare reform fees year over year outweighed lower targeted marketing investment and productivity gains. R&D expanded 18% YoY operationally on planned investment in priority oncology and obesity programs, including several Phase 3 study starts. Acquired IPR&D fell 52% YoY operationally on the $650M Innovent charge booked this quarter, against a $1.35B 3SBio charge in the prior-year quarter — a flattering comp that management flagged directly rather than hiding.

2. FY2026 Guidance — Raised Across the Board, COVID Reaffirmed

Item	FY2026 guidance	Change
Revenue	$62–64B	Raised $1.5B at the midpoint
Adjusted diluted EPS	$2.95–3.05	Raised and narrowed; +$0.10 at the midpoint while absorbing the $0.10/share Innovent impact
COVID products	~$4B	Reaffirmed; majority of Comirnaty revenue expected in Q4, consistent with vaccination season; Paxlovid utilization tied to infection rates and treatment demand
R&D expense	$10.8–11.8B	Now-guided full-year range
Adjusted gross margin	Mid-70s% range	Embedded in the updated outlook
All other components	Reaffirmed	—

The raise is self-financed in an unusual sense: EPS moves up at the midpoint by exactly the amount of dilution the Innovent collaboration put into reported IPR&D, meaning the underlying raise is larger than headline math suggests but sits entirely on the non-COVID business. The COVID reaffirmation is a Q4-dependent call — Comirnaty’s sales remain seasonal, and Paxlovid’s FY2026 trajectory rides on respiratory infection rates management cannot control. The guide’s credibility lever for Q4 is therefore concentrated: non-COVID discipline (proven) plus a normal vaccination season (assumed).

3. The Launch-and-Acquire Engine

Cohort item	Q3 FY2026	Notes
Launched-and-acquired products revenue	$3.8B	+32% YoY operational; the cohort management targets against LOE headwinds
Padcev	+$255M YoY	Largest driver; anchors legacy Seagen growth
Nurtec	+$135M YoY	+33% YoY operational; leading the oral CGRP class in the U.S. with UK/Italy/Japan expansion
Lorbrena	+$114M YoY	Third-largest driver
Acquired-product portfolio (overall)	+37% YoY operational	Bourla: “good progress” in maximizing value of the big three acquisitions
Legacy Seagen U.S. revenue	+39% YoY	Driven by Padcev

Pfizer has now deployed the capital for this engine: “over the last few years, we have invested close to $80 billion in transactions that equipped us with key products contributing to current commercial momentum and platforms with transformative potential,” Bourla said, estimating about 80% went to [Seagen], [Metsera], and [Biohaven]. Beyond revenue, management claims the Seagen deal “expanded our ability to discover oncology breakthroughs, doubling the size of our early-stage pipeline at the time we closed the acquisition.” The stated purpose of continued investment behind the cohort is explicitly defensive-offensive: “We continue to invest behind this group of products to mitigate LOE headwinds over the next several years.”

The engine also now has an international proof case in China, where Wegovy launched at the end of April 2026. Alexandre de Germay walked through the commercial machinery: approval of the type 2 diabetes indication at the end of October 2026 opened hospital and e-commerce channels; the product passed national reimbursement (NRDL) committees starting in June, with the final reimbursement review expected by the end of this month; and since competitors already have reimbursement access, approval plus reimbursement together would mark “the start of market penetration.” Bourla framed the global obesity commercial model as Viagra-era economics — large out-of-pocket willingness, dramatically different international market sizing, e-commerce-first behavior — and pointed to Pfizer for All, the company’s consumer web channel, as infrastructure Pfizer already owns, while noting AI is changing promotion “even more importantly at the patient’s level.”

4. Pipeline Proof Points

Albert framed the cadence up top: “In recent months, we achieved 2 key regulatory decisions, 1 key pivotal readout, and 8 key pivotal study starts alongside strong data we presented at several recent medical congresses.” The detailed evidence follows below.

Hematology — elranatamab: repositioning to first relapse

MM-32, the internally discovered BCMA bispecific’s newest Phase 3, tested fixed-dose monotherapy against investigator’s choice of 3 established standard-of-care regimens in the growing CD38-refractory setting. The interim showed the statistically significant, clinically meaningful PFS improvement, and more than 75% of patients had not experienced disease progression or death from any cause at data cut (with the 18-month PFS estimate in Highlights). Safety was “consistent and potentially differentiated”: because infection prophylaxis was designed into MM-32 from the start, grade-3-or-higher infection rates ran lower than in MM-5 — the earlier readout where prophylaxis was not in place at study start, having been instituted only after early infection deaths concentrated in China and 2 other countries during the COVID wave, skewing MM-5’s overall hazard ratio. MM-5’s fuller data arrive at a medical meeting before year-end. The strategic claim: fixed-dose monotherapy from first relapse regardless of prior CD38 exposure, plus newly diagnosed-disease studies underway, make the eligible patient population able to grow approximately 5-fold pending clinical and regulatory success.

Breast cancer — atemaciclib and the endocrine stack

Atemaciclib is positioned as a potential first-in-class, highly selective CDK4 inhibitor (33x CDK4-versus-CDK6 selectivity) to sit on top of — and, in early disease, potentially replace — today’s first-line HR+ backbone. FORLIGHT-1’s Phase 2 enrolled 92% of patients within 3 months of stopping a CDK4/6 inhibitor and delivered the reduction in risk of progression or death (in Highlights) versus investigator’s choice of fulvestrant or everolimus plus exemestane — in a refractory population. In early disease, the atemaciclib-plus-letrozole Phase 2 achieved complete cell-cycle arrest in 88% of participants’ tumors versus 18% on letrozole alone. The early-stage Phase 3, combining atemaciclib with the SERD gerridestrant, is planned “within the next few months,” designed aligned with regulators on the expected approval of gerridestrant in this setting; the first-line Phase 3 versus investigator’s choice is ongoing. Cross-trial tolerability against approved backbones: grade-3-plus neutropenia numerically lower with no grade 4/5 seen, any-grade diarrhea below abemaciclib and comparable to palbociclib/ribociclib, and dose reductions at 14% versus 32–43% for approved agents. Complementary pieces: provetristat (a KAT6 inhibitor) and a PI3K program — a new internally discovered PIK3CA inhibitor’s Phase 1 was posted on ClinicalTrials.gov last week, zovigalacib (pan-alpha isoform-selective) advances in a Relay study, and gedatolisib is also Pfizer-discovered; the combination logic with atemaciclib is the absence of drug-drug interactions other CDK4/6 inhibitors show in PIK3CA combinations, which management called “potentially significant advantage” against PIK3CA mutation carriers (up to 40% of ER+ tumors, 20–25% of HER2+).

NSCLC — tevonatamab, with a bladder kicker

The PD-1/VEGF bispecific has dosed over 1,200 patients globally with a consistent safety record and runs 2 ongoing Phase 3 trials with 2 more expected to begin this year. Beyond the response-rate advance (Highlights), median PFS ran nearly 14 months in both squamous and non-squamous first-line NSCLC on the pivotal dose plus doublet chemotherapy — an improvement of roughly 4 to 5 months versus comparators — with the in-study control arms landing consistent with pembrolizumab’s historical Phase 3 benchmark and the ivonescimab cross-trial read flagged for its limitations. The franchise also has a bladder program: study 309, a bladder-sparing Padcev-plus-pembrolizumab trial just started, and a planned Phase 3 combining Padcev with tevonatamab that should start later this year. On the VOLGA data AstraZeneca released (raising the prospect of fewer Padcev cycles in muscle-invasive bladder cancer), Boshoff’s read was reinforcing — but with the caveats that VOLGA enrolled a cisplatin-ineligible population, delivered lower pathological complete remission rates than pembro-plus-Padcev with slightly lower event-free survival, and left open which curative-intent patients can actually be de-escalated.

Inflammation & immunology — telrecomec: a trispecific with head-to-head ambition

Telrecomec, designed in-house to target IL-4, IL-13, and TSLP simultaneously, posted placebo-adjusted Phase 2 atopic dermatitis response rates of about 50% on EASI-75 at top monthly doses — data management argues suggest potential superiority over dupilumab, the standard-of-care biologic. The Phase 3 program (2 studies, one including a head-to-head against dupilumab) powers its key secondary endpoints to test precisely that hypothesis. Safety at subcutaneous doses up to 400 milligrams once every 4 weeks showed conjunctivitis and injection-site reactions both lower than dupilumab’s reported rates and comparable to placebo. Severe-asthma and moderate-to-severe COPD studies are underway with molecule readouts expected 2028–2029, and the target pathways are validated across 9 diseases by approved therapies today.

Vaccines — PCV25/PCV35 succession planning

The pediatric candidate met the historical two-fold post-dose-4 IgG criterion with all 20 serotypes shared with Prevnar 20 — but since the 2023 pediatric licensure of Prevnar 20, the FDA applies a more stringent 1.5-fold non-inferiority standard now built into the Phase 3 design, where modeling (with tighter confidence intervals on the much larger sample) predicts the threshold clears for at least 22 of 25 serotypes (per Highlights). The commercial ambition is best-in-class: serotype coverage reaching an estimated 84% of invasive pneumococcal disease in U.S. children under 5 — roughly 25 percentage points beyond Prevnar 20 — strung together through seroresponse data, functional OPA titers, and a totality-of-evidence approach. The Phase 3 lot-to-lot consistency study is fully enrolled. In adults, PCV35 extends the enhanced serotype-3 technology validated with PCV25 to other key serotypes, with a Phase 1 start expected this year.

Prostate — meprometastat (MEVPRO)

MEVPRO programs support approval of meprometastat, the in-house discovered, potential first-in-class EZH2 inhibitor meant to expand the prostate franchise behind Xtandi. Data at ESMO included a compelling 8.9-month PFS figure. On the Q&A timelines: MEVPRO-1 now reads out in Q1 2027 based on the current event rate, MEVPRO-2 was corrected on the call to Q4 2027 per the updated ClinicalTrials.gov entry, and these remain event-driven studies. Commercially, Aamir Malik emphasized the multi-indication franchise plan and fully global economics versus Xtandi’s split arrangement with Astellas, which currently holds only half the U.S. rights.

Metabolic portfolio — berobenatide and the amylin program

Berobenatide, the investigational monthly subcutaneous GLP-1 peptide, anchors 10 active and planned Phase 3 trials in 2026 — including one evaluating a switch from approved weekly therapies — with enrollment already strong across the pivotal program. The amylin combination program advanced its Phase 2b together with the single-agent arm to full enrollment; the SOLIS-1 study tests amylin alone and amylin-plus-berobenatide across different doses and titrations, with the efficacy readout expected in the second half of 2027. Management is targeting the first of a series of potential approvals for berobenatide in 2028, with go-to-market planning underway. New Phase 3 indications starting now include knee osteoarthritis and obstructive sleep apnea (with or without PAP), more announcements are promised in the coming months, and additional backbone studies — potentially extending toward oncology endpoints — are flagged for 2027.

5. Cost, Capital, and the LOE Bridge

The savings story has two active phases. Phase one is on track to deliver nearly all of its $7.2B of net savings by end-2026 (per Highlights), distributed across manufacturing footprint and cost of goods, R&D (reinvested rather than banked), and SG&A (commercial, marketing, and general overhead). Phase two, announced last quarter, targets an additional $2.5B of net savings from 2027 through 2029, split between SG&A and manufacturing costs — explicitly designed, per Cecile Guegan, to “translate into savings” that “mitigate the margin erosion as part of the LOE transition in 2027 to 2029.”

On operating expense structure itself, Umar Rafat’s question forced the issue: after the 2022 comparability premise in Lowlights, the CFO’s defense was that Q3 SG&A carried “some one-time dynamics” while full-year guidance still embeds a SG&A decline versus last year.

Capital allocation is unchanged in priority order — reinvest at appropriate returns, maintain and grow the dividend over time, preserve flexibility including share repurchases — with an $80B-scale M&A program still working through the P&L because it loaded the balance sheet: leverage ended the quarter at 2.6x, slightly below the 2.7x target, and is expected to stay around current levels or modestly higher through the LOE transition. Liquidity and flows support both sides of the ledger: operating cash flow of $8.8B came in year-to-date through Q3, $9.2B went to internal and external R&D in the first 9 months alongside $7.3B returned via the quarterly dividend, and BD capacity stands at approximately $6B after the Innovent transaction closed. Buybacks are deferred rather than dead: “As we go post-LOE period, our operating cash flow grows with the levers and we have other options to continue to increase shareholder value.”

6. Pricing and Policy Watch

U.S. healthcare policy reached this P&L hard this quarter. The expected net-price consequence of the January 1 Eliquis price decrease (Lowlights) has begun to land, and management described otherwise-stable gross-to-net dynamics driven by volume and “strong market performance.” The 2027 stack is bigger: two products enter Medicare’s negotiated-price program that year, the 340B credit/rebate model starts in January, and the impacts of the government pricing agreement (MFN) arrive on top — all items, per Cecile, to be reflected in 2027 guidance rather than commented on today. These are policy mechanics now, not tail risks: the agreement with the government underwrites the tariff-relief and pricing-rating logic that the whole 2027 bridge is being built on.

7. What to Make of the Street Gap

Bourla devoted serious Q&A time to a modeling gap he considers indefensible — thin pipeline coverage (the count is in Lowlights) and, beyond the pipeline, material discrepancies on already launched products. Two examples he gave, both Street figures management is quoting from sell-side models: Nurtec is already at close to $2B annualized at Pfizer while “the Street has us almost $2.5 billion by year 2030”; and for the competing multiple-myeloma franchise next to elranatamab, “the Street is forecasting $5 billion and for us $600 million” — a gap he called “not justifiable, even with the current information,” while conceding the tolerability edge he is claiming “remains to be proven.” His proposed resolution mechanism is informational, not financial: “as more information is coming for the performance actually of the new products, I think the Street probably will start adjusting their numbers.”

The long-range anchor sits here too: “We have line of sight to our aim of delivering a risk-adjusted high single-digit revenue CAGR from year-end 2028 through year-end 2033.” Bridging to that base year is a 2027 guidance delivered, per Cecile, “around the middle of December like we did last year,” whose drags (LOEs for U.S. Ibrance/Xtandi plus international Eliquis at end-2026; the 2027 pricing stack above) face the offsetting ramp of the launched-and-acquired portfolio this section’s growth numbers already evidence.

Conclusion

This is a quarter where the earned-credibility side of the ledger actually has weight for the first time in a while: a self-financing guidance raise, an operating engine that can grow into thirty-percent-type numbers inside a mature pharma P&L, and a pipeline section that reads like independent confirmation rather than corporate narration. The unresolved question is sequencing — the acquired portfolio and cost program lift 2026 and 2027 as the LOE wall lands, but the re-rating assets (obesity, NSCLC bispecifics, prostate energy, immunology head-to-heads) mostly pay off at or after the 2028 base year where the growth-day claim is anchored. The market now needs a reason to price the bridge, not just the destination; the mid-December 2027 guide is the first hard test, and four quarters of it — proving the growth engine survives its own decelerating seed — is the investment decision. Until then, the positives are real but still provisional against the drag structure.

Artifacts and Follow-Ups

Key Artifacts — highest priority

FY2026 delivery against the raised guide: revenue baseline $62–64B and adjusted-EPS baseline $2.95–3.05 — Q4’s Comirnaty-heavy COVID commentary and Paxlovid’s infection-rate dependence versus the ~$4B COVID line are the swing factors that confirm or refute the raise. Watch the Q4 print’s non-COVID growth rate against the 7% YoY operational mark.
2027 guidance, delivered around mid-December: the first formal arithmetic of the bridge — LOEs (U.S. Ibrance/Xtandi plus others; international Eliquis at end-2026) against the launched-and-acquired ramp, the $2.5B second-phase savings program, and the 2027 pricing stack — is either absorbed or exposed here.
elranatamab’s data path: MM-5’s fuller efficacy and safety data are expected at a medical meeting before year-end; the topic is whether the hazard-ratio history (prophylaxis timing, infection-death geography) and the 5-fold population-expansion case hold up in front of investors.
The atemaciclib/gerridestrant sequencing commitment: the early-stage Phase 3 combining the two begins “within the next few months” upon an expected gerridestrant approval in this setting — a dated regulatory-and-trial-start claim this management team owns if it slips.
Obesity program cadence into readout: with 10 active and planned Phase 3 trials in 2026, the SOLIS-1 amylin Phase 2b fully recruited, and first approvals targeted from 2028, the 2H-2027 SOLIS-1 efficacy readout is the program’s anchor event — watch for the promised additional Phase 3 announcements (knee OA, OSA with or without PAP already started).

Secondary Tracking Items

MEVPRO-1’s Q1 2027 readout and MEVPRO-2’s corrected Q4 2027 timeline (updated on ClinicalTrials.gov during the quarter).
Wegovy China: the NRDL final reimbursement review expected at the end of October, which — combined with the T2D indication approval — governs how fast the launch scales.
Telrecomec’s Phase 3 atopic dermatitis progression and the severe-asthma (2028) and moderate-to-severe-COPD readouts (2028–2029).
PCV25 Phase 3 progress toward the FDA’s 1.5-fold standard and the PCV35 adult Phase 1 start expected this year.
The STAT6 readout expected later this year.
Lyme vaccine regulatory state: CHMP opinion expected in 2027, with an FDA-related update promised for Q4 2026.
Legacy Seagen U.S. growth sustainability and whether the cohort keeps compounding against the LOE drag that arrives in 2027.
Leverage’s trajectory relative to target through the LOE transition and the timing buybacks actually resume.